CASI - CASI Pharmaceuticals, Inc.
| Previous Close | 3.2100 |
| Open | 3.2400 |
| Bid | 3.2300 x 900 |
| Ask | 3.2500 x 1000 |
| Day's Range | 3.1900 - 3.2500 |
| 52 Week Range | 2.7300 - 5.2000 |
| Volume | 18,008 |
| Avg. Volume | 187,032 |
| Market Cap | 310.123M |
| Beta (3Y Monthly) | 1.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
CASI Pharmaceuticals Announces The Promotion Of Larry Zhang To President
ROCKVILLE, Md. , Sept. 19, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products, ...
- PR Newswire
China NMPA Accepts Clinical Trial Application For CASI's CD19 CAR-T-Product
ROCKVILLE, Md. , Sept. 16, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products, ...
- PR Newswire
CASI Pharmaceuticals, Inc. To Present At The 2019 H.C. Wainwright 21st Annual Global Investment Conference
ROCKVILLE, Md. , Sept. 3, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products ...
- PR Newswire
CASI Pharmaceuticals Announces Launch of EVOMELA® (melphalan for injection) in China
ROCKVILLE, Md. , Aug. 12, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products ...
- PR Newswire
CASI Pharmaceuticals Announces Second Quarter and First Half 2019 Financial and Business Results
-Acquired Exclusive Rights to Commercialize Anti-CD19 T-Cell Therapy in China and Worldwide -Acquired Exclusive Worldwide Rights to CID-103, a Novel Anti-CD38 Monoclonal Antibody -EVOMELA® (Melphalan Hydrochloride ...
- PR Newswire
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
ROCKVILLE, Md., June 17, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a U.S. biopharmaceutical company that is focusing on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, the U.S., and throughout the world, announces the signing of a license agreement for exclusive worldwide license and commercialization rights to an autologous anti-CD19 T-cell therapy product (CNCT19) from Juventas Cell Therapy Ltd., a China-based domestic company located in Tianjin City, China. Juventas will continue to develop CNCT19 with CASI's participation on the program's steering committee. CASI will be responsible for payment of certain future development milestones and sales royalties.
- PR Newswire
CASI Pharmaceuticals To Present At The 2019 BIO International Convention
ROCKVILLE, Md. , June 3, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company with a platform to develop and accelerate the launch of innovative therapeutics ...
- PR Newswire
CASI Pharmaceuticals Announces First Quarter 2019 Financial and Business Results
- Acquired Exclusive Global Rights to CID-103, a Novel Anti-CD38 Monoclonal Antibody - Entered into China Distribution Agreement for EVOMELA® (Melphalan Hydrochloride for Injection) - Received National ...
- PR Newswire
INVESTOR ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers
NEW YORK , April 18, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
- PR Newswire
CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics
Under the terms of the agreement, CASI has obtained global rights to TSK011010 for an upfront payment of 5 million euros and an equity investment of 2 million euros, as well as certain milestone and royalty payments. The equity investment will be made in a newly established company of Black Belt Therapeutics focusing on novel immuno-oncology targets. CASI will be responsible for all development and commercialization activities of the TSK011010 program.
- PR Newswire
CASI Pharmaceuticals Announces The Appointment Of Wei-Wu He, Ph.D., Executive Chairman, To The Role Of Chief Executive Officer
ROCKVILLE, Md., April 2, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a U.S. pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world, announced that Wei-Wu He, Ph.D., Executive Chairman of CASI, has been appointed Chief Executive Officer. Dr. He will continue to serve as Chairman of the Board of Directors. Dr. He succeeds Ken K. Ren, Ph.D. who for personal reasons is stepping down from his role as Chief Executive Officer but will remain on the Company's Board of Directors.
- PR Newswire
CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results And Business Results
- Announced distribution partner for Melphalan Hydrochloride for Injection (EVOMELA®) to support commercialization in China following NMPA approval in December of 2018 - Announced NMPA approval of CTAs ...
- PR Newswire
CASI Pharmaceuticals Announces Exclusive Distribution Partner For Melphalan Hydrochloride For Injection (EVOMELA®) In China
ROCKVILLE, Md. , March 13, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. based pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products ...
- PR Newswire
CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Registration Trial For MARQIBO®
ROCKVILLE, Md. , March 7, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. based pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products ...
- GlobeNewswire
Report: Developing Opportunities within Pure Storage, Flowers Foods, Cognex, CASI Pharmaceuticals, Ellie Mae, and Douglas Emmett — Future Expectations, Projections Moving into 2019
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire
CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN®
ROCKVILLE, Md. , Feb. 19, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. based pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products ...
- PR Newswire
CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
ROCKVILLE, Md. , Feb. 6, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical ...
- ACCESSWIRE
These 4 Healthcare Stocks Are Heating Up
CORAL GABLES, FL / ACCESSWIRE / December 28, 2018 / The healthcare industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. From data-based approaches and analysis consumer demands/needs, advancements in the sector may catalyze potential opportunities for those looking to healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Akers Biosciences Inc (AKER), CASI Pharmaceuticals Inc (CASI), and Rite Aid Corporation (RAD) represent 4 healthcare companies innovating towards the future. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced, earlier this month that as part of its overarching strategy to cover major verticals associated with primary care, it had signed into a binding Letter of Intent (LOI) agreement to acquire a Vancouver-based pharmacy.
- ACCESSWIRE
The 4 Healthcare Stocks To Watch On Monday
CORAL GABLES, FL / ACCESSWIRE / December 3, 2018 / Attention on Healthcare Market has continued to accelerate this quarter. The global healthcare IT market is expected to post a CAGR of over 8% during the period 2018-2022, according to the latest market research report by Technavio.
- PR Newswire
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)
National Medical Products Administration Approves Melphalan Hydrochloride For Injection (EVOMELA®) as Treatment for Specific Uses in Patients with Multiple Myeloma ROCKVILLE, Md. , Dec. 3, 2018 /PRNewswire/ ...
- GlobeNewswire
Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire
CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China
The facility will be designed and constructed based on global cGMP requirements and is expected to have capacity for large scale production. The facility will be a key asset supporting CASI's growth and commercialization plans with further agreements to be finalized and site construction to begin in mid-2019.
- PR Newswire
CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results
- Key new hires include Chief Financial Officer and President, CASI China as CASI prepares for global commercialization efforts - Acquired U.S. FDA-approved abbreviated new drug application (ANDA) from ...
- ACCESSWIRE
Today’s Research Reports on Stocks to Watch: CASI Pharmaceuticals and Therapix Biosciences
NEW YORK, NY / ACCESSWIRE / October 24, 2018 / Biotech stocks CASI Pharmaceuticals and Therapix Biosciences were both seeing big gains on acquisition news. CASI has acquired a U.S. FDA-approved abbreviated ...
- ACCESSWIRE
3 Healthcare Stocks Trending Higher On News
Today, we're exploring 3 stocks to watch that are focusing on building their business in the health related markets including Premier Health Group, Inc. ( PHGRF)(PHGI.CN), Symbililty Solutions Inc. (TSX-V:SY.V)(OTC PINK: ATBEF), and CASI Pharmaceuticals, Inc. (CASI). Premier Health Group, Inc. (PHGRF)(PHGI.CN)’s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. With new access to things like the telemedicine technology that HealthVue offers, the technology allows users to see virtual HealthVue doctor through the telemedicine app/website (Government funded in BC, therefore no additional cost to the patient).